Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 9th April 2018 - Draft

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the 12th March 2018 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- **Methoxyflurane 99.9% 3 mL liquid inhalation vapour (Penthrox®) (Galen)**

Requested by the Burns Team for the relief of acute pain due to dressing changes. Penthrox is licensed for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain. The intention is that Penthrox will replace inhaled nitrous oxide and reduce the use of opioid analgesics. Penthrox will also allow relatively faster discharge of patients and associated cost savings. This is intended for out-patient use.
This application has been submitted following the undertaking of an informal trial undertaken on the Burns Unit involving FOC stock provided by the manufacturer administered to 19 patients.
Decision: Approved for addition to the formulary

Ex-panel

- **Doxepin 50mg Capsules**

25mg capsules are currently included on the formulary.
The maintenance dose for Doxepin is 25mg - 300mg. There are a number of patients at WMUH site who are prescribed 50mg TDS. It is more convenient for these patients to take 3 capsules per day rather than 6. It is also more cost effective to provide 50mg capsules rather than 25mg capsules.
Decision: Approved for addition to the formulary

- **Gelclair Oral Gel**

Gelclair oral gel has been shown to reduce the pain of oral conditions in adults following cancer therapy (Berndtson, 2001) and in palliative care (Innocenti et al, 2002). It was the focus of a preliminary clinical study that GOSH was involved in (study results awaiting publication). It is also being prescribed for children with oral pain after chemotherapy and bone marrow transplant within the Children's Cancer Unit at GOSH.
Gelclair oral gel is accepted as a Class 1 device as it is not pharmacologically active within the EU and by the MHRA and is listed in the Drug Tariff Part IXA appliances as an oral film-forming agent. There is currently very high usage at CWH site. Highlighted by a formulary review undertaken as part of the Cerner project
Decision: Approved for addition to the formulary

- **High use Dermatology Products**

PIGMANORM CREAM - Used now instead of DEPIGMENTING HRH CUTANEOUS SOLUTION for Vitaligo and Melasma
SILICONE (DERMATIX) GEL - Dressing supplied from Pharmacy for Keloid scarring
SILICONE (KELO-COTE) GEL - Dressing supplied from pharmacy for Keloid scarring
DIPROSONE 0.05% OINTMENT - Topical steroid – this is not on NWL formulary
Highlighted by a formulary review undertaken as part of the Cerner project
Decision: Approved for addition to the formulary

Removals

- **Low use Dermatology Products**

Proposal to remove the following items from the formulary where there is very low usage:
SALICYLIC ACID 2% IN AQUEOUS CREAM

SALICYLIC ACID 4% IN AQUEOUS CREAM
BENZOYL PEROXIDE 2.5% GEL
CALCIPOTRIOL 50MCG/G CREAM
CICATRIN POWDER (Neomycin)
CLOTRIMAZOLE 1% DUSTING POWDER
COAL TAR (CRUDE) 10% IN WSP
COAL TAR (CRUDE) 5% IN WSP
COAL TAR (SOLUTION) 3% IN WSP
DEPIGMENTING HRH CUTANEOUS SOLUTION
DERMALO BATH EMOLLIENT
PROPYLENE GLYCOL 40% IN UNG MERCK
PSORIN 1% SCALP GEL
PSORIN OINTMENT
Highlighted by a formulary review undertaken as part of the Cerner project
Decision: Approved for removal from the formulary

- **Doxepin 10mg Capsules**

Discontinued by the manufacturer
Decision: Approved for removal from the formulary

- **Diclofenac 50mg Dispersible Tablets**

Discontinued by the manufacturer
Decision: Approved for removal from the formulary

- **Peginterferon alfa 2a 135mcg Pre-filled Syringe (Pegasys)**

Discontinued by the manufacturer
Decision: Approved for removal from the formulary

- **Peginterferon alfa 2a 180mcg Pre-filled Syringe (Pegasys)**

Discontinued by the manufacturer
Decision: Approved for removal from the formulary

- **Daclizumab 150mg Pre-filled Syringe (Zinbryta®)**

The European Medicines Agency (EMA) has recommended the immediate suspension of the marketing authorisation and recall of Daclizumab (Zinbryta) in the EU following reports of serious inflammatory brain disorders, including Encephalitis and Meningoencephalitis, in patients with Multiple Sclerosis
Decision: Approved for removal from the formulary

- **NHS England Consultation re. Items which should not routinely be prescribed in Primary Care**

Proposal to remove the following medicines from the formulary following the publication of the NHS England Consultation re. Items which should not routinely be prescribed in Primary Care

- **Dosulepin 25mg Capsules**
- **Dosulepin 75mg Tablets**
- **Omega-3 Fatty Acids Capsules**
- **Trimipramine 25mg Tablets**
- **Trimipramine 50mg Capsules**

Decision: Approved for removal from the formulary

NICE Approved drug applications

- **TA498 - Lenvatinib with everolimus for previously treated advanced**

renal cell carcinoma
Application form for NICE approved drug approved by NICE in February 2018
Decision: Approved for addition to the formulary

- **TA500 - Ceritinib for untreated ALK-positive non-small-cell lung cancer**

Application form for NICE approved drug approved by NICE in February 2018
Decision: Approved for addition to the formulary

- **TA505 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma**

Application form for NICE approved drug approved by NICE in February 2018
Decision: Approved for addition to the formulary

Pharmacoeconomic Board requests

- **Rituximab for Opsoclonus Myoclonus Syndrome**

Request to Pharmacoeconomic Board which was approved on 07/03/2018.
Decision: Noted

- **Eltrombopag for Thrombocytopenia**

Request to Pharmacoeconomic Board which was approved on 22/03/2018.
Decision: Noted

4.2 Trust Medicines Policy
Nil

4.3 Medicines Optimisation

- **Contrast Medical Vial Sharing - Risk Assessments**

Deferred to next month as the presenter did not attend at the meeting
Decision: Deferred to next month

- **Accessible Information Standard: Pharmacy Guideline for Medicines Information Provision**

This is a new policy that was presented for approval. The Trust is required to make reasonable adjustments to services for people with learning difficulties and also those who may be sight impaired, or audio impaired. This is the Pharmacy related policy that details the medicine related adjustments. This policy details how to provide medicines related information to patients via the use of braile, large font, hearing loop or easy read formatting. It explains how to identify patients on Lastword (at CXWH site) who have visual or hearing impairment or learning difficulties.
This policy provides details of how to contact RNIB for leaflets that need to be translated. Although this guideline is for pharmacy staff, it can be shared Trustwide as it highlights the Pharmacy resources available in the Trust to meet this standard and other departments will be required to do similar. This policy has been discussed with the Trust Quality Impact Group. The easy read leaflet has been approved by the Trust Information Leaflet Group.
Decision: Approved

4.4 NICE Technical Appraisals and Guidance
NICE Technical Appraisals

7 Appraisals were published in March 2018

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

TA508 - Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
Formulary status / Action
N/A - This is a procedure. No impact on formulary. We are not set up currently to provide this procedure at this trust.

TA509 - Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Formulary status / Action
Oncologists to provide number of patients that will be treated. Application not required.
Currently included on the formulary

TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Oncology Team

TA511 - Brodalumab for treating moderate to severe plaque psoriasis
Formulary status / Action
Was approved for use as part of an EAS in December 2017.
Add to the formulary following receipt of a signed application form from the Dermatology Team

TA512 - Tivozanib for treating advanced renal cell carcinoma
Formulary status / Action
NHS England will only commission this for a few specialist centres. C&W has not been declared a specialist centre. Currently being queried with NHSE.

TA513 - Obinutuzumab for untreated advanced follicular lymphoma
Formulary status / Action
Add to the formulary following receipt of a signed application form from the Oncology Team

TA514 - Regorafenib for previously treated advanced hepatocellular carcinoma
Formulary status / Action
Nil - Not recommended

4.5 IVIG Update

- **IVIG requests**

March 2018
CWH Site
There were 22 IVIG issues, with 6 new requests

WMUH Site
There were 17 IVIG issues, with 2 new requests
Decision: Approved

4.6 Items for noting

- **NHS England: Immunoglobulin IV availability**

Letter from NHS England re Immunoglobulin IV availability. It was noted that for ITP a Single dose is recommended only. It was also noted that Public Health England recommend IVIg for Tetanus, which is not in the National IVIg Guidelines.
Decision: Noted

- **EMA: New measures to avoid valproate exposure in pregnancy**

Letter from EMA re New measures to avoid valproate exposure in pregnancy. Bulletin re-enforcing this is currently being drafted by the Medication Safety Group.
Decision: Noted

- **NHS England: Principles for shared care between primary and secondary care/tertiary care**

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Letter from NHS England re Principles for shared care between primary and secondary care/tertiary care. This guidance outlines when GPs will take responsibility of ongoing prescribing. It discusses the support that needs to be in place for a GP that may not feel confident to take responsibility or if a GP is not up -to-date with the concerned medication. There is a need to review the current contract with NWL and for CCGs to review this guidance and what changes, if any, need to be made to the relevant procedures. The guidance also provides a template for drafting shared care guidance.
Decision: Noted

- **Trust Patient Safety Group Report - April 2018**

Report submitted to Patient Safety Group for April 2018
Decision: Noted

- **CPP Report - March 2018**

CPP report for March 2018
Decision: Noted

- **Patient Group Directions**

Patient Group Direction Trackers for CWH and WMUH
Decision: Noted

- **Medicines Safety Bulletin (Issue 2)**

Medicines Safety Bulletin re Similar Sounding Drugs
Decision: Noted

- **MHRA Drug Safety Update - March 2018**

MHRA update for March 2018
Decision: Noted

4.7 Meeting minutes for noting

- **Medication Safety Group Meeting - January 2018**

Minutes from Medication Safety Group Meeting - January 2018
Decision: Noted

- **Chemotherapy Service Group (CSG) - January 2018**

Minutes from Chemotherapy Service Group (CSG) - January 2018
Decision: Noted

4.8 Additional papers to go to Trust patient Safety Group
Nil

5. Any other business
Nil

6. Date of next meeting
Next meeting
Date: Monday 14th May 2018
Time: 8am-9am
Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)
Closing date: 20th April 2018